Table 1 Baseline patient characteristics (n = 55)
Parameter | Number of patients |
|---|---|
Sex | |
Male | 36 |
Female | 19 |
Age, years (range) | 64 (21–79) |
Performance status | |
0 | 49 |
1 | 6 |
Primary site | |
Colon | 33 |
Rectosigmoid | 3 |
Rectum | 19 |
Tumor differentiation | |
well | 13 |
moderate | 36 |
poor | 2 |
others | 3 |
unknown | 1 |
Adjuvant chemotherapy | |
Yes (%) | 12 (21.8 %) |
Uracil and tegafur plus leucovorin | 5 |
Capecitabine | 5 |
5-FU/LV | 1 |
Uracil and tegafur | 1 |
Primary tumor resection (%) | 37 (67.3 %) |
Assessable lesion | |
No | 2 |
Yes | 53 |
Metastatic sites | |
Liver | 32 |
Lung | 23 |
Lymph node metastases | 13 |
Peritoneal dissemination | 4 |
other metastases | 11 |
Number of metastatic sites | |
1 | 29 |
2 | 17 |
≥3 | 9 |
Liver limited disease (%) | 14 (25.4 %) |
CEA (median, range) | 21.2 (2.3–8577.6) |
CA19-9 (median, range) | 38.8 (0.7–328,230) |